[HTML][HTML] Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options
P Vodicka, P Klener, M Trneny - OncoTargets and Therapy, 2022 - ncbi.nlm.nih.gov
Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60–70%
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …
chance of cure with current R-CHOP chemoimmunotherapy. However, 30–40% of patients …
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical
outcomes. Our understanding of its molecular makeup continues to improve risk …
outcomes. Our understanding of its molecular makeup continues to improve risk …
The future of immunotherapy for diffuse large B‐cell lymphoma
J Duell, J Westin - International journal of cancer, 2025 - Wiley Online Library
With the introduction of anti‐CD19 chimeric antigen receptor (CAR) T‐cell (CAR T)
therapies, bispecific CD3/CD20 antibodies and anti‐CD19 antibodies, immunotherapy …
therapies, bispecific CD3/CD20 antibodies and anti‐CD19 antibodies, immunotherapy …
New treatment options in elderly patients with diffuse large B-cell lymphoma
A Arcari, F Cavallo, B Puccini, D Vallisa - Frontiers in Oncology, 2023 - frontiersin.org
Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (> 65 years of age) and
this population is expected to increase in the following years. A simplified geriatric …
this population is expected to increase in the following years. A simplified geriatric …
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
T Lu, J Zhang, ZY Xu-Monette, KH Young - Experimental Hematology & …, 2023 - Springer
Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line
immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse …
immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse …
Diffuse large B‐cell lymphoma
A Barraclough, E Hawkes, LH Sehn… - Hematological …, 2024 - Wiley Online Library
Large B‐cell lymphoma, the prototype of aggressive non‐Hodgkin lymphomas, is both the
most common lymphoma and accounts for the highest global burden of lymphoma‐related …
most common lymphoma and accounts for the highest global burden of lymphoma‐related …
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
is the most commonly used regimen for the upfront treatment of diffuse large B-cell …
is the most commonly used regimen for the upfront treatment of diffuse large B-cell …
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study
Abstract Treatment of diffuse large B-cell lymphoma (DLBCL) in older patients is
challenging, especially for those who are not eligible for anthracycline-containing regimens …
challenging, especially for those who are not eligible for anthracycline-containing regimens …
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients …
doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients …
[HTML][HTML] Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL
J Munoz, A Deshpande, L Rimsza… - Cancer Treatment …, 2024 - Elsevier
In treating diffuse large B-cell lymphoma (DLBCL), oncologists have traditionally relied on
the chemotherapy backbone of R-CHOP as standard of care. The two dangers that the …
the chemotherapy backbone of R-CHOP as standard of care. The two dangers that the …